Vaxcyte, Inc. (5VA)
Munich
Real-time Data
06:00 AM
Day's Range
53.5052 wk Range
26.20Overview - 5VA - Vaxcyte, Inc.
Key Statistics
Valuation
Enterprise Value
4.33B
P/E (Trailing)
‪-9.32‬
PEG Ratio
‪-0.15‬
Price / Book
‪3.28‬
EV / EBITDA
‪-4.40‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-22.60%‬
Return on Equity
‪-36.51%‬
Ownership
Shares Outstanding
144.78M
Float
136.17M
Held by Insiders
‪0.48%‬
Held by Institutions
‪113.44%‬
Price stats
Beta
‪1.21‬
50-Day Avg
‪48.86‬
200-Day Avg
‪45.97‬
Dividends
Payout Ratio
‪0.00%‬
Market Cap - 5VA - Vaxcyte, Inc.
Peers - 5VA - Vaxcyte, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on Munich.
- 5VAMunichVaxcyte, Inc.7.96BMarket Cap+50.65%52-week change-9.50P/E (Trailing)‪0.00%‬Profit Margin
- 1AEAMunichargenx SE American Depositary Receipt54.10BMarket Cap+32.96%52-week change40.04P/E (Trailing)‪32.26%‬Profit Margin
- 0QFMunichModerna, Inc.47.90BMarket Cap+81.73%52-week change25.19P/E (Trailing)‪-141.42%‬Profit Margin
- 1HMMunichAdaptive Biotechnologies Corporation3.49BMarket Cap+50.16%52-week change-56.23P/E (Trailing)‪-20.72%‬Profit Margin
- 4DNMunichDenali Therapeutics Inc.3.42BMarket Cap+38.19%52-week change-7.22P/E (Trailing)‪0.00%‬Profit Margin
- 30JMunichIdeaya Biosciences Inc.2.55BMarket Cap+31.06%52-week change-21.08P/E (Trailing)‪-62.17%‬Profit Margin
- 0GTMunichStoke Therapeutics Inc.1.63BMarket Cap+70.11%52-week change47.80P/E (Trailing)‪0.00%‬Profit Margin
Profile Summary - 5VA - Vaxcyte, Inc.
About
Vaxcyte Inc. is a biotechnology company focused on developing innovative vaccines for preventing infectious diseases. The primary objective of the company is to create safer and more effective vaccines using its proprietary cell-free protein synthesis platform, a groundbreaking technology that aims to enhance vaccine…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
